Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer  

作　　者：Han Li Shumin Yuan Han Wu Yajie Wang Yichen Ma Xiance Tang Xiaomin Fu Lingdi Zhao Benling Xu Tiepeng Li Peng Qin Hongqin You Lu Han Zibing Wang 

机构地区：[1]Department of Immunotherapy,The Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital,Zhengzhou,China [2]Department of Oncology,Qilu Hospital of Shandong University,Jinan,China [3]Biotherapy Center,The First Affiliated Hospital of Zhengzhou University,Zhengzhou,China [4]Nanchang University Queen Mary School,Nanchang,China [5]The First Clinical Medical College of Xinjiang Medical University,Urumqi,China [6]Department of Medical Affairs,The Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital,Zhengzhou,China

出　　处：《Cancer Innovation》2024年第6期76-85,共10页肿瘤学创新（英文）

基　　金：National Natural Science Foundation of China,Grant/Award Number:81972690;Medical Science and Technology Research Project of Health Commission of Henan Province,Grant/Award Number:YXKC2021007。

摘　　要：Background:This study evaluated the efficacy and safety of low‐dose anlotinib combined with immune checkpoint inhibitors as second‐line or later treatment for extensive‐stage small cell lung cancer(ES‐SCLC).Methods:The study included 42 patients with ES‐SCLC who were treated with low‐dose anlotinib combined with programmed cell death protein 1/programmed cell death‐ligand 1 inhibitors at Henan Cancer Hospital between March 2019 and August 2022.We retrospectively analyzed the efficacy and safety data for these patients.Indicators assessed included progression‐free survival(PFS),overall survival(OS),the overall response rate(ORR),the disease control rate(DCR),and adverse events(AEs).Prognostic factors were identified in univariate and multivariate analyses.Results:Median PFS was 11.0 months(95%CI:7.868–14.132)and median OS was 17.3 months(95%CI:11.517–23.083).The ORR was 28.5%and the DCR was 95.2%.Treatment‐related AEs were noted in 27 patients(64.3%),the most common of which was thyroid dysfunction(26.2%).Grade 3/4 treatmentrelated AEs were observed in two patients(4.8%).Conclusions:A combination of low‐dose anlotinib and immune checkpoint inhibitors as second‐line or later treatment for ES‐SCLC may achieve longer PFS and OS and have manageable AEs.

关 键 词：combination immunotherapy extensive‐stage small cell lung cancer immune checkpoint inhibitors low‐dose antiangiogenic drugs 

分 类 号：R734.2[医药卫生—肿瘤]